Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
The study is to evaluate the clinical efficacy of apatinib mesylate tablets combined with
PD-1 in the treatment of recurrent and metastatic nasopharyngeal carcinoma after IMRT with
concurrent chemotherapy,including The Overall Response Rate (ORR), Progression-free survival
(PFS),Overall survival (OS),and Toxicities.
Phase:
Phase 2
Details
Lead Sponsor:
Wei Jiang
Collaborators:
Guangxi Naxishan Hospital People's Hospital of Laibin People's Hospital of Lingshan Wuzhou Red Cross Hospital